Daniel Pichl - 10 Feb 2025 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief People Officer
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Issuer symbol
SWTX
Transactions as of
10 Feb 2025
Net transactions value
-$795,039
Form type
4
Filing time
12 Feb 2025, 20:01:39 UTC
Previous filing
14 Jan 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Options Exercise $380,050 +13,750 +27% $27.64 64,512 10 Feb 2025 Direct F1
transaction SWTX Common Stock Options Exercise $442,240 +16,000 +25% $27.64 80,512 10 Feb 2025 Direct F1
transaction SWTX Common Stock Sale $728,998 -13,750 -17% $53.02 66,762 10 Feb 2025 Direct F1, F2
transaction SWTX Common Stock Sale $488,260 -9,000 -13% $54.25 57,762 10 Feb 2025 Direct F1, F3
transaction SWTX Common Stock Sale $400,072 -7,000 -12% $57.15 50,762 10 Feb 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Options Exercise $0 -13,750 -31% $0.000000 31,250 10 Feb 2025 Common Stock 13,750 $27.64 Direct F1, F5
transaction SWTX Stock Option (Right to Buy) Options Exercise $0 -16,000 -33% $0.000000 32,750 10 Feb 2025 Common Stock 16,000 $27.64 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 21, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.515. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person.
F6 Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.